论文部分内容阅读
目的:观察纳洛酮对肺性脑病患者治疗的效果及安全性。方法:肺性脑病患者50例随机分为观察组和对照组。所有患者均通过无创呼吸机进行持续吸氧,对照组患者给予常规治疗,观察组患者在对照组治疗基础上加用纳洛酮治疗,7 d为1个疗程。观察两组患者的临床疗效、相关临床指标及药品不良反应发生情况。结果:观察组总有效率为92.00%,高于对照组的72.00%,但差异无统计学意义(P>0.05)。两组患者治疗后的pH水平、PaO_2及PaCO_2水平、血管紧张素Ⅱ及白细胞介素-8(IL-8)水平均较治疗前明显改善(P<0.05),且治疗后观察组各项指标均明显优于对照组(P<0.05)。两组药品不良反应发生率差异无统计学意义(P>0.05)。结论:早期应用纳洛酮治疗肺性脑病临床指标明显改善,不良反应发生率少,安全性高,值得在临床上推广使用。
Objective: To observe the effect and safety of naloxone on patients with pulmonary encephalopathy. Methods: Fifty patients with pulmonary encephalopathy were randomly divided into observation group and control group. All patients were continuously ventilated by noninvasive ventilator. Patients in the control group were given routine treatment. The patients in the observation group were treated with naloxone on the basis of the control group, and the course of treatment was 7 days. To observe the clinical efficacy of two groups of patients, related clinical indicators and adverse drug reactions. Results: The total effective rate in the observation group was 92.00%, which was higher than that in the control group (72.00%), but the difference was not statistically significant (P> 0.05). After treatment, the levels of PaO 2 and PaCO 2, the levels of angiotensin Ⅱ and interleukin-8 (IL-8) in both groups were significantly improved after treatment (P <0.05), and after treatment, the indicators in the observation group Were significantly better than the control group (P <0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P> 0.05). Conclusion: The early application of naloxone in the treatment of pulmonary encephalopathy improved significantly clinical indicators, less adverse reactions, high safety, it is worth promoting in clinical use.